A new international consensus report on precision medicine in diabetes prevention and care has been published in Nature Medicine.

The report, with Dr Siew Lim, from Australia-based Monash University’s Eastern Health Clinical School, as the co-senior lead, highlights the importance of precision diabetes medicine in clinical practice, while also emphasising the critical knowledge gaps that must be addressed.

Supported by the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD) and the Novo Nordisk Foundation, the consensus report was made possible through a huge collaborative effort involving 200 academic experts from 28 countries under the banner of the Precision Medicine in Diabetes Initiative (PMDI).

The report, which is the second international consensus report on precision diabetes medicine, highlights significant advancements in the adoption of precision medicine in diabetes prevention, diagnosis, treatment and prognosis while also shedding light on numerous knowledge gaps.

The consensus report shows clear progress in implementing precision diabetes medicine, shedding light on opportunities for its immediate or near-term clinical application, such as in diagnosing and treating monogenic diabetes.

Precision medicine also shows potential in the prevention of gestational diabetes.